Gansu: 68 drug waste standards, 3 exclusive varieties in the column!

Pharmaceutical Network June 23 - June 22, Gansu Province Drug and Medical Supplies Centralized Procurement Network issued "on the application for the withdrawal of waste drugs to cancel the bid to register the network qualification of the notice (hereinafter referred to as "Notice"), a total of musk live hemorrhoids, injection muscles 68 drugs from 40 manufacturers, such as glycoside, emergency syrup, compound catoplylic tablets, injection of pyrethroid sodium, erythromycin intestinal solution tablets, hydrochloric acid renitin injections, submitted applications for withdrawal due to production line transformation, rising costs, shortage of raw materials, and discontinuation of production.For this withdrawal of waste species, the province encourages other enterprises to apply for the same type of drugs to apply for the sun hanging network, the cost-effective than the platform has been bid to hang the network of drugs to implement a record-free sunshine hanging network.So, what should be done with the discarded variety? Gansu clearly stipulates: the same rules accumulated 3 bad records or notification of criticism, warnings, the number of bad records is greater than or equal to 10 times, cancel the hanging net of the rulesThe same enterprise has more than 2 (including 2) product regulations to cancel the hanging net, the enterprise is blacklisted, the enterprise may not participate in the next round of drug collection activities in Gansu Province; It can be seen that, regardless of the origin, the active abolition is not a temporary "sleep" so simple, it is likely to affect its normal bidding in the province.Three channels "replacement" on the upperaccording to the "notice" introduced, because the above-mentioned drugs can not guarantee the normal supply of medical institutions in the province, in order to maintain the normal procurement order, Gansu Province to the withdrawal of waste to ensure the supply of corresponding measures:1exclusive varietiesThis batch of 3 exclusive varieties apply for withdrawal, including Guizhou Liansheng Pharmaceuticals musk live hemoine cream (7cm x 10cm) since January 1, 2019 since the purchase volume of 0; Since January 1, 2019, the stock volume of 230009, the distribution rate of 100%, Hubei Ketian Pharmaceutical castor oil (20ml) since January 1, 2019 in the inventory volume of 300, the distribution rate of 100%After the above three rules are removed, medical institutions may choose to purchase alternative drugs with the same function.2Exclusive winning bid hanging net drugThis batch of 8 drugs in the province's drug procurement platform / exclusive bid hook network, after the withdrawal of medical institutions can choose the same function of the main treatment of alternative drug procurement, while Gansu Province will start the emergency green channel sunshine hanging network, so that the same varieties of other unmarked network enterprises to declare .　　3 Other This batch of a total of 57 de-waste drugs, the platform has the same variety, different specifications of the winning net drugs can be guaranteed supply .　　In fact, Hainan Province has 250 previously applied for the cancellation of the network, and Shanxi Province has also 25 pharmaceutical manufacturers in 66 product regulations, applied for its withdrawal of direct network product platform hanging network qualification "A lot of provinces have a similar situation, and due to rising production costs caused by the withdrawal of waste is more concentrated, " said one For enterprises, on the one hand, tender
need to continue to reduce prices On the other hand, for some raw materials are too expensive, inevitably loss of cheap drugs, enterprises are not willing to produce, or even forced to stop production In this case, pharmaceutical companies must guarantee supply has become a major pain point "
, for example, the exclusive product contains musk drugs, China's musk resources from the 1950s nearly 3 million head down to now less than 100,000 head The cost of RAW materials is bullish, the result is that the enterprise can not supply normally, according to the provisions of light scrap bid, cancel the bid eligibility, deduct the performance bond, heavy into the bad record, cancel all products of the enterprise in the province's winning bid qualification, or even be kicked out of the provincial market for two years .　　The failure to accept the letter will be severely punished
since the enterprise actively applied for the abolition of the bid, the consequences are not serious? .　　According to Gansu's practice: In order to ensure the normal procurement of medical institutions, from June 24, Gansu Province will cancel the above-mentioned withdrawal of drugs bid network qualification, and in accordance with the "Gansu Province Drug Centralized Procurement Integrity Management Measures" to give enterprises a warning, record a bad record and other treatment, before the implementation of the complaint to accept the challenge .　　Prior to this, the State Medical Insurance Bureau issued the "guidance on the establishment of pharmaceutical prices and recruitment credit evaluation system (second draft for comments)" "pharmaceutical prices and recruitment credit evaluation of the operating norms (draft for comments)," the Medical Insurance Bureau intends to establish a list of pharmaceutical prices and recruitment of breach of trust, and the pharmaceutical enterprises in the local tender procurement market to assess the breach of trust as general, medium, serious, particularly serious four levels, dynamic updates quarterly .　　Experts believe that this rating will have an important impact on pharmaceutical production and operation activities, thereby promoting the integrity of enterprises, fair competition Taking the credit rating as "particularly serious" pharmaceutical enterprises as an example, the document requires that, in addition to warnings and warnings and warnings, the enterprise should suspend all drug hanging network, bidding or distribution qualifications, the suspension period of pharmaceutical enterprises credit repair, grade changes .